Ioversol
Optiray (ioversol) is a small molecule pharmaceutical. Ioversol was first approved as Optiray 320 on 1988-12-30.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Optiray
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ioversol
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
OPTIRAY 300 | Liebel-Flarsheim | N-019710 RX | 1992-01-22 | 1 products, RLD, RS |
OPTIRAY 350 | Liebel-Flarsheim | N-019710 RX | 1992-01-22 | 1 products, RLD, RS |
OPTIRAY 320 | Liebel-Flarsheim | N-019710 RX | 1988-12-30 | 1 products, RLD, RS |
OPTIRAY 300 | Liebel-Flarsheim | N-020923 RX | 1999-05-13 | 1 products, RLD, RS |
OPTIRAY 320 | Liebel-Flarsheim | N-020923 RX | 1998-05-29 | 1 products, RLD, RS |
OPTIRAY 350 | Liebel-Flarsheim | N-020923 RX | 1998-05-28 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
optiray | New Drug Application | 2023-02-17 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | IOVERSOL |
INN | ioversol |
Description | Ioversol is an amidobenzoic acid. |
Classification | Small molecule |
Drug class | iodine-containing contrast media |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I |
Identifiers
PDB | — |
CAS-ID | 87771-40-2 |
RxCUI | 27792 |
ChEMBL ID | CHEMBL1200614 |
ChEBI ID | — |
PubChem CID | 3741 |
DrugBank | DB09134 |
UNII ID | N3RIB7X24K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,106 documents
View more details
Safety
Black-box Warning
Black-box warning for: Optiray
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more